title: [Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus].
abstract: Anti-diabetic drugs have, in addition to their well-known glucose lowering-effect, different effects in the rest of cardiovascular factors that are associated with diabetes mellitus. Glucagon-like peptide-1 (GLP-1) receptor agonists have recently been incorporated to the therapeutic arsenal of type 2 diabetes mellitus. The objective of this review is to summarize the available evidence on the effect of the GLP-1 receptor agonists on different cardiovascular risk factors, mediated by the effect of GLP-1 receptor agonists on the control of hyperglycaemia and the GLP-1 receptor agonists effect on other cardiovascular risk factors (weight control, blood pressure control, lipid profile and all other cardiovascular risk biomarkers). In addition, we present the emerging evidence with regards to the impact that GLP-1 receptor agonists therapy could have in the reduction of cardiovascular events and the currently ongoing studies addressing this issue.
authors: Unidad de Hipertensión y Riesgo Vascular, Servicio de Medicina Interna, Instituto Clínico de Medicina y Dermatología, Hospital Clínic-IDIBAPS, Universidad de Barcelona, Barcelona, España. camafort@clinic.ub.es
authors: Miguel
authors: M
authors: Camafort-Babkowski
mesh_terms: D001786:Blood Glucose / Q000032:analysis; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000150:complications / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D050171:Dyslipidemias / Q000150:complications; D000077270:Exenatide; D005746:Gastric Emptying / Q000187:drug effects / Q000502:physiology; D052216:Glucagon-Like Peptide 1 / Q000819:agonists* / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000502:physiology / Q000627:therapeutic use; D006321:Heart / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D007328:Insulin / Q000096:biosynthesis / Q000378:metabolism; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000187:drug effects / Q000378:metabolism; D000069450:Liraglutide; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D015201:Meta-Analysis as Topic; D009765:Obesity / Q000150:complications / Q000188:drug therapy; D010455:Peptides / Q000494:pharmacology / Q000627:therapeutic use*; D012306:Risk; D014688:Venoms / Q000494:pharmacology / Q000627:therapeutic use*; D015431:Weight Loss
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D010455:Peptides; D014688:Venoms; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1; D000077270:Exenatide
keywords: Cardiovascular risk; Diabetes mellitus tipo 2; Glucagon-like peptide-1; Péptido tipo 1 similar al glucagón; Riesgo cardiovascular; Type 2 diabetes mellitus